September 17, 2009
Posted by on
The Ontario Bioscience Industry Organization (OBIO) and the Ministry of Research and Innovation (MRI) co-hosted an event a few days ago entitled: “Funding Opportunities in 2009-2010 for Bioscience Companies: What CEO’s Need to Know About Ontario’s ETF and BIP Programs.”
The speakers were:
- Chair: Kevin French, Senior Act. Manager, RBC;
- Rocky Ganske (President & CEO, Axela),
- Peter Pekos (President & CEO, Dalton Pharmaceuticals),
- Tom Wellner (President & CEO, Therapure Biopharma);
- Rob Koturbash (Managing Director, Maple Leaf Angels)
- Steve Ottaway (Managing Director, GMP Securities),
- Peter van der Velden (CEO, Lumira Capital);
- John Marshall (Director, MRI, responsible for OETF)
- Ryan Lock (Acting Director, MRI, responsible for BIP)
Lots of great information on funding opportunities, and luckily, the whole thing is archived (here) online. To access the presentation, enter “OBIO” when prompted.
July 15, 2009
Posted by on
Pfizer Global Research and Development is contributing $6 million and the Ontario government is contributing $900,000, through the Biopharmaceutical Investment Program (BIP), for a new project “to discover and validate new targets for the diagnosis, prognosis and treatment of colorectal cancer.” Brad Wouters, a Senior Scientist with the Ontario Cancer Institute (OCI) and a Senior Investigator at the Ontario Institute for Cancer Research (OICR), will lead the project.
Here’s the scoop from the OICR press release:
“Dr. Wouters and a team of scientists at OCI and OICR will use genomic and molecular pathology approaches and develop a large clinical biobank to identify molecular signatures in colorectal cancer. These molecular signatures will be used to accelerate the development of biomarkers for early detection, monitoring and treatment of cancer.”
The Canadian Press article includes some additional background info on the project, which Paul Lévesque, president of Pfizer Canada, says began with a trip by Ontario researchers to meet Pfizer scientists in San Diego almost two years ago.
May 19, 2009
Posted by on
The speeches (s-peach-es?) just finished this morning at the Ontario Premier’s breakfast.
Minister of Research and Innovation John Wilkinson announced that Ontario has recently completed 2 new BIP investments:
Ontario’s Premier — Dalton McGuinty, winner of BIO’s second annual International Leadership Award — spoke next, highlighting the Ontario Innovation Agenda, including BIP, business tax reductions and recent funding in the Emerging Technologies Fund and the new $100 million for genomics research.
Dr. Nagy also spoke, emphasizing the $100 million of new funding and the value of a peer group of 95 P.I.’s in Ontario working on stem cells and regenerative medicine. Current work focuses on cell type switching without regression to pluripotency.
On to the omelet…
P.S. First time here at the Cross-Border Biotech Blog? Welcome! Check out who we are, check out our Trends in 2009 series, or hit the search and navigation tools on your right and see if you see anything interesting.